

Nexsen secures first hospital partner in Asia

Nexsen Limited (ASX:NXN) (Nexsen or the Company) is pleased to announce it has entered into a binding term sheet with GHK Hospital Limited (GHK), a subsidiary of IHH Healthcare Berhad (MYX: IHH, SGX: Q0F), establishing a strategic collaboration framework for the clinical validation, real-world data generation and commercialisation of Nexsen's rapid point-of-care diagnostic platform.

GHK owns the Gleneagles Hospital Hong Kong, a 500-bed multi-specialty private tertiary hospital, which is also a private teaching hospital with The University of Hong Kong as its exclusive partner.

Investor Highlights:

- **Binding term sheet signed with GHK Hospital Limited**, operator of a 500-bed multi-specialty private tertiary hospital, to establish a strategic collaboration framework for Nexsen's rapid point-of-care diagnostic platform
- **Access to relevant patient populations and real-world hospital workflows**, enabling Nexsen to progress clinical validation, generate real-world evidence, and assess reimbursement feasibility and potential future adoption pathways for its diagnostic products
- **Backed by IHH Healthcare's global hospital network**, one of the world's largest healthcare groups, with an approximate market capitalisation of AU\$27 billion, operating 190 healthcare facilities across 10 countries, including 89 hospitals, clinics and ambulatory care centres
- **Platform expansion opportunity**, with the collaboration including potential joint R&D, grant applications and co-development of future diagnostic products beyond Nexsen's initial development pipeline, targeting unmet clinical needs
- **Third foundational partner of our Asia-Pacific strategy**, each of which has been delivered with non-dilutive funding, alongside:
 - HK\$6 million IGNITE Grant funding Nexsen's establishment of dedicated research and development facilities in Hong Kong
 - UM-Nexsen Joint Research Facility being established at Universiti Malaya Innovative Medical Devices Centre of Excellence co-funded by UM

Managing Director, Mark Muzzin, commented:

"Nexsen has built its platform with world-class research partners to solve diagnostic gaps where faster answers can materially improve clinical decision making. The collaboration with GHK moves that work into a leading hospital environment, giving Nexsen access to specialist clinicians, relevant patient populations and real-world workflows where our rapid diagnostics can be clinically assessed and refined for future adoption.

"This partnership materially strengthens Nexsen's ability to execute its Asia-Pacific strategy, providing a critical bridge between product development and real-world adoption across one of the world's most important healthcare regions."

Regional Chief Executive Officer of IHH Healthcare North Asia, Dr Kenneth Tsang commented:

“IHH Healthcare North Asia is committed to advancing clinical excellence and improving patient outcomes through innovation, value-based care and strategic partnerships.

“Nexsen’s rapid point-of-care diagnostic platform is a compelling example of the type of innovation that can support more timely clinical decision-making in real-world healthcare settings. The ability to deliver accurate diagnostic insights closer to the patient has the potential to improve workflows, support clinicians and address gaps in care that can impact treatment timing.

“We look forward to exploring this collaboration with Nexsen, beginning with clinical validation and real-world assessment of its diagnostic platform in relevant patient populations.”



Nexsen Managing Director Mark Muzzin and IHH Healthcare North Asia Regional CEO Dr Kenneth Tsang at the signing ceremony for the GHK Hospital Limited collaboration, held at the Asia Summit on Global Health and witnessed by H.E. Mr Scott Dewar, Australian Ambassador to the People’s Republic of China.

Partnership framework

Under the agreement, Nexsen and GHK intend to progress a broad strategic collaboration across GHK and its affiliated IHH entities in North Asia and Nexsen’s research and commercialisation activities.

The collaboration encompasses clinical validation of Nexsen’s point-of-care tests in relevant patient populations, generation of real-world data to inform clinical workflows and care pathways, and assessments of price points and reimbursement feasibility in Hong Kong and across other healthcare markets where GHK’s affiliated entities through the IHH Healthcare network operate, with a focus on North Asia.

The framework also extends to joint educational and training activities to support appropriate product utilisation by clinicians and other healthcare professionals, and joint research, development and grant collaborations, including applications for Hong Kong Government, regional and international grants.

Critically, the framework is designed to establish the clinical evidence base, pricing considerations, reimbursement understanding and clinician familiarity required to support potential future adoption of Nexsen’s diagnostics by GHK’s and its affiliated entities in North Asia. By assessing Nexsen’s products within

For personal use only

GHK's clinical validation and workflow assessment processes, the collaboration creates a pathway from development through to potential future use and adoption in real-world hospital settings.

The parties intend to develop the framework into one or more definitive agreements covering the proposed collaboration within six months.

Advancing our Asia-Pacific strategy

The GHK collaboration is Nexsen's third operational entry in its Asia-Pacific commercialisation strategy, adding a direct hospital-based validation and potential adoption pathway in North Asia.

In March, the Company was awarded a HK\$6 million IGNITE Grant supporting clinical validation of StrepSure® through established Hong Kong hospital networks and the establishment of in-region research, development and manufacturing capability. This was followed by the UM-Nexsen Joint Research Facility at Universiti Malaya, Malaysia's oldest university and a globally recognised research institution, establishing a dedicated R&D and commercialisation hub co-funded by UM and extending the applicability of Nexsen's platform into food safety diagnostics.

Through GHK and IHH, Nexsen now adds a leading hospital partner to validate and potentially adopt its diagnostics across GHK and the broader IHH North Asia network.

Together, these initiatives provide Nexsen with an integrated Asia-Pacific platform spanning research, clinical validation, grant-supported development, manufacturing readiness and future adoption pathways, while continuing to leverage partner funding and institutional support to advance the Company's diagnostics from development toward real-world clinical use.

Outlook

The parties will now progress discussions toward one or more definitive agreements to formalise specific workstreams under the collaboration framework within the six-month period contemplated by the term sheet. Initial activities are expected to focus on clinical validation and real-world assessment of Nexsen's lead diagnostics, for Group B Streptococcus and Kidney Function, within GHK and its affiliated entities in North Asia, with additional diagnostic applications to be scoped progressively as Nexsen's broader suite of diagnostics advances toward clinical readiness.

Nexsen's core regulatory programs continue to advance in parallel, including U.S. clinical site activation and progression toward FDA 510(k) submission, as previously disclosed.

The Company also continues to progress other partnership and collaboration opportunities across Asia, including for StrepSure®, its rapid point-of-care diagnostic for Group B Streptococcus, and suite of Kidney Function diagnostics targeting Acute Kidney Injury and Chronic Kidney Disease.

-ENDS-

ASX release authorised by the Board of Directors.

For more information, please contact:

Corporate Enquiries

e: corporate@nexsen.bio

w: www.nexsen.bio

a: Suite 1005, 4 Bridge Street, Sydney NSW 2000, Australia

Company Secretary

e: NXN@reignadvisory.com

p: 61 2 9174 5388

About GHK Hospital Limited

GHK Hospital Limited owns Gleneagles Hospital Hong Kong, a 500-bed multi-specialty private tertiary hospital, which is also a private teaching hospital with The University of Hong Kong as its exclusive partner.

GHK is part of IHH Healthcare, a leading multinational healthcare provider shaping the future of care.

IHH operates across 10 countries, including Malaysia, Singapore, Türkiye, India, and Greater China, with a team of 76,000 team delivering world-class excellence every day, within and beyond our 190 healthcare facilities, including more than 89 hospitals. Our comprehensive services span the full healthcare continuum, from primary care to complex treatments complemented by diagnostics, imaging, rehabilitation, telehealth, and home care. IHH's market capitalisation on Bursa Malaya is approx. MYR 77.8 billion (AUD 27 billion).

About Nexsen Limited (ASX: NXN)

Nexsen is developing a suite of rapid point-of-care diagnostics designed to deliver lab-grade results for conditions that have traditionally depended on delayed laboratory testing. The company is focused on areas of significant unmet clinical need, where faster diagnosis can improve patient outcomes and reduce pressure on healthcare systems.

Nexsen's lead diagnostic is the GBS Rapid Sensor, a rapid point-of-care diagnostic for detecting Group B Streptococcus, addressing a critical unmet need in maternal health. The Company is also developing rapid kidney function diagnostics for Acute Kidney Injury and Chronic Kidney Disease, two conditions that affect more than 850 million people globally and remain underserved by slow, lab-based diagnostics.

With further diagnostics in development across human health, ag-tech and biosecurity, Nexsen aims to become a global leader in rapid point-of-care diagnostics, delivering on its mission to ensure every person benefits from a Nexsen test at some point in their life.

Forward Looking Statements Disclaimer

Forward looking statements are typically identified by the use of forward looking terminology such as 'aims', 'believes', 'expects', 'may', 'will', 'could', 'should', 'seeks', 'intends', 'estimates', 'plans', 'assumes', 'envisages', or the negative thereof or other words of similar meaning. Examples of such forward looking statements include, among others, statements or discussions regarding the Company's business, financial or investment strategies, regulatory and product rollout strategies, estimates of expenditure, present or future plans or events, prospects, growth, objectives for future operations and estimates. Such forward looking statements include matters that are not historical facts and are subject to a number of risks and uncertainties, many of which are beyond the Company's control and all of which are based on the Company's current beliefs, intentions or expectations about future events. Such statements are, by their nature, subject to a number of known and unknown risks, uncertainties, assumptions and other important factors that could cause actual results, performance or achievements to differ materially from any expected future results, performance or achievements expressed or implied, by the forward looking statement.

Neither the Company nor any person gives any representation, assurance or guarantee that the occurrence of the event expressed or implied in any forward looking statements in this document will actually occur and you are cautioned not to place undue reliance on such forward looking statements. Factors that might cause forward looking statements to differ materially from actual results, performance or achievements include, among other things, global economic conditions, economic conditions in jurisdictions in which the Company may operate or invest, credit markets, legislative fiscal and regulatory developments, the effects of continued volatility in markets and exchange rate fluctuations. The forward looking statements contained in this document speak only as of the date this document and each of the Company, respective directors, officers, employees, agents, representatives and/or advisers expressly disclaims any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this document.

For personal use only